The global contraceptive market size was estimated to be USD 29.45 billion in 2023 and is expected to reach at USD 64.1 billion by 2033 with a CAGR of 7.32% during the forecast period 2023-2033. Increasing prevalence of Sexually Transmitted Diseases (STDs), surge in demand for contraceptive drugs & device by women’s population, rising user awareness levels, growing number of unintended pregnancies, increasing government initiatives regarding the usage of contraceptives against STDs and unwanted pregnancies, surge in adoption of oral pills, rising health concerns associated with teen pregnancies, and rising technological advancements by market players are some of the key factors boosting the market growth.
Rising technological advancements by market players is predicted to boost the market growth during the forecast period. For instance, in June 2021, Emme, a health tech company that initially introduced a smart case and app for birth control tracking, has now broadened its services to include prescription delivery and telemedicine. This expansion, known as EmmeRx, enables patients in 16 states to conveniently obtain contraception prescriptions and have them delivered to their location.
By Product, Contraceptive devices was the highest revenue-grossing segment in the global contraceptive market in 2022 owing to growing awareness regarding STDs & the efficiency of condoms to prevent infections such as HIV, increasing demand of condoms, and rising launch of new products by market players. Additionally, Contraceptive drugs is predicted to grow at fastest CAGR during the forecast period owing to the rise in number of purchases made by public sector entities, surge in demand for birth control pills, and increasing product approvals. For instance, in April 2021, The USFDA granted approval to Mayne Pharma for NEXTSTELLIS (3mg drospirenone (DRSP) and 14.2mg estetrol (E4) tablets) as a contraceptive method to prevent pregnancy.
By Gender, Male was the highest revenue-grossing segment in the global contraceptive market in 2022 owing to surge in demand for male birth control devices such as condoms and rising launch of new products. Additionally, Female is predicted to grow at fastest CAGR during the forecast period owing to the growing incidences of unwanted pregnancies, rising technological advancements, and increasing launch of advanced tools by market players. For instance, In March 2021, Clue introduced a digital contraceptive that utilizes statistical prediction of ovulation as a birth control method for users.
By Distribution Channel, Retail pharmacies was the highest revenue-grossing segment in the global contraceptive market in 2022 owing to the growing demand for contraceptive pills and surge in launch of new products by market players. For instance, in July 2021, MHRA granted approval to HRA Pharma to release an over-the-counter (OTC) contraceptive pill (Desogestrel-only pill) in the U.K. Additionally, Online pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of e-commerce, ease of ordering medication at home, and rising technological advancements.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing incidence of abortion, growing population of women, rising patient awareness, surge in launch of generic & low-cost drugs & devices, increasing demand for contraceptives by teenagers, and growing initiatives by key market players for women’s health. For instance, in November 2020, AbbVie revealed a collaboration with esteemed organizations such as the American College of Obstetricians and Gynecologists, the Endometriosis Association, Healthy Women, the International Pelvic Pain Society, GE Healthcare, and Black Women's Health Imperative. The primary objective of this partnership is to enhance the quality of life for the one in ten women of reproductive age in the United States who are affected by this condition. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in government initiatives, rising demand for population control, and increasing product approvals by regulatory bodies. For instance, in May 2020, Phexxi, the first non-hormonal birth control gel, obtained approval from the USFDA for Evofem Biosciences Inc.
Rising technological advancements by market players is predicted to boost the market growth during the forecast period. For instance, in June 2021, Emme, a health tech company that initially introduced a smart case and app for birth control tracking, has now broadened its services to include prescription delivery and telemedicine. This expansion, known as EmmeRx, enables patients in 16 states to conveniently obtain contraception prescriptions and have them delivered to their location.
By Product, Contraceptive devices was the highest revenue-grossing segment in the global contraceptive market in 2022 owing to growing awareness regarding STDs & the efficiency of condoms to prevent infections such as HIV, increasing demand of condoms, and rising launch of new products by market players. Additionally, Contraceptive drugs is predicted to grow at fastest CAGR during the forecast period owing to the rise in number of purchases made by public sector entities, surge in demand for birth control pills, and increasing product approvals. For instance, in April 2021, The USFDA granted approval to Mayne Pharma for NEXTSTELLIS (3mg drospirenone (DRSP) and 14.2mg estetrol (E4) tablets) as a contraceptive method to prevent pregnancy.
By Gender, Male was the highest revenue-grossing segment in the global contraceptive market in 2022 owing to surge in demand for male birth control devices such as condoms and rising launch of new products. Additionally, Female is predicted to grow at fastest CAGR during the forecast period owing to the growing incidences of unwanted pregnancies, rising technological advancements, and increasing launch of advanced tools by market players. For instance, In March 2021, Clue introduced a digital contraceptive that utilizes statistical prediction of ovulation as a birth control method for users.
By Distribution Channel, Retail pharmacies was the highest revenue-grossing segment in the global contraceptive market in 2022 owing to the growing demand for contraceptive pills and surge in launch of new products by market players. For instance, in July 2021, MHRA granted approval to HRA Pharma to release an over-the-counter (OTC) contraceptive pill (Desogestrel-only pill) in the U.K. Additionally, Online pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of e-commerce, ease of ordering medication at home, and rising technological advancements.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing incidence of abortion, growing population of women, rising patient awareness, surge in launch of generic & low-cost drugs & devices, increasing demand for contraceptives by teenagers, and growing initiatives by key market players for women’s health. For instance, in November 2020, AbbVie revealed a collaboration with esteemed organizations such as the American College of Obstetricians and Gynecologists, the Endometriosis Association, Healthy Women, the International Pelvic Pain Society, GE Healthcare, and Black Women's Health Imperative. The primary objective of this partnership is to enhance the quality of life for the one in ten women of reproductive age in the United States who are affected by this condition. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in government initiatives, rising demand for population control, and increasing product approvals by regulatory bodies. For instance, in May 2020, Phexxi, the first non-hormonal birth control gel, obtained approval from the USFDA for Evofem Biosciences Inc.
Segmentation: Contraceptive Market Report 2022 - 2033
Contraceptive Market Analysis & Forecast by Product 2022 - 2033 (Revenue USD Bn)
Contraceptive Devices
- Vaginal Rings
- Subdermal Implants
- Diaphragm
- Condoms
- Female Condoms
Male Condoms
- IUDs
- Hormonal IUDs
- Copper IUDs
Contraceptive Drugs
- Injectables
- Contraceptive Pills
- Patch
Contraceptive Market Analysis & Forecast by Gender 2022 - 2033 (Revenue USD Bn)
- Female
- Male
Contraceptive Market Analysis & Forecast by Distribution Channel 2022 - 2033 (Revenue USD Bn)
- Retail Pharmacies
- Online Pharmacies
Contraceptive Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Contraceptive Market: Product Estimates & Trend Analysis
8. Contraceptive Market: Gender Estimates & Trend Analysis
9. Contraceptive Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Contraceptive Market
12. Europe Global Contraceptive Market
13. Asia Pacific Global Contraceptive Market
14. Latin America Global Contraceptive Market
15. MEA Global Contraceptive Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Cupid Ltd.
- Pfizer Inc.
- Bayer AG
- Helm AG
- Veru Inc.
- Abbvie Inc.
- Agile Therapeutics
- Viatris (Mylan)
- Janssen Pharmaceuticals Inc.
- Afaxys Inc.
- Church & Dwight
- Organon Group Of Companies
- China Resources Zizhu Pharmaceutical Co. Ltd. (CR Zizhu)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 29.45 Billion |
| Forecasted Market Value ( USD | $ 64.1 Billion |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
